Tildacerfont: New Drug Provides Hope, Treatments After 50-Year-Long Drought
Photo by Pablo Heimplatz on Unsplash
Spruce Biosciences Appoints Renowned Drug Developer Kirk Ways, M.D., Ph.D. to Board of Directors
Dr. Ways’ Expertise in Late-Stage Clinical Development in Therapeutics Areas of High Unmet Medical Meet Supports Spruce’s Goal to Expand Portfolio of Indications for Tildacerfont
The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy’s Launches Generic Vascepa, Halozyme Strikes Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 21)
48 Biggest Movers From Yesterday
Gainers
Lydall, Inc. (NYSE: LDL) shares jumped 85.4% to close at $61.72 on Monday after the company agreed to be acquired by Unifrax for $61.10 per share.
Stocks That Hit 52-Week Lows On Monday
During Monday's morning session, 22 companies made new 52-week lows.
Stocks That Hit 52-Week Lows On Friday
Before 10 a.m. ET on Friday, 29 companies hit new 52-week lows.
The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira’s CEO Placed On Temporary Leave, 5 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 17)
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 15)